Kintara Therapeutics Cash on Hand 2010-2024 | HURA

Kintara Therapeutics cash on hand from 2010 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.

Kintara Therapeutics Cash on Hand 2010-2024 | HURA

Kintara Therapeutics cash on hand from 2010 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$170.2B
Vertex Pharmaceuticals (VRTX)$123.4B
Gilead Sciences (GILD)$107.4B
Regeneron Pharmaceuticals (REGN)$106.8B
Bristol Myers Squibb (BMY)$105.7B
CSL (CSLLY)$97.7B
GSK (GSK)$79.1B
Alnylam Pharmaceuticals (ALNY)$37.5B
Argenex SE (ARGX)$33.5B
Biogen (BIIB)$26.9B
BioNTech SE (BNTX)$26.5B
Illumina (ILMN)$23.1B
BeiGene (BGNE)$21.4B
Moderna (MRNA)$20.7B
Genmab (GMAB)$15.1B
BioMarin Pharmaceutical (BMRN)$13.3B
Vaxcyte (PCVX)$12.9B
Exact Sciences (EXAS)$12.8B
Incyte (INCY)$12.6B
Insmed (INSM)$12.4B
Sarepta Therapeutics (SRPT)$12.1B
Bio-Techne Corp (TECH)$11.2B
QIAGEN (QGEN)$9.6B
Bio-Rad Laboratories (BIO.B)$9.3B
Roivant Sciences (ROIV)$8.6B
Repligen (RGEN)$8.4B
Exelixis (EXEL)$8.2B
Intra-Cellular Therapies (ITCI)$8.1B
Revolution Medicines (RVMD)$8B
Legend Biotech (LEGN)$7.9B